Dasatinib NDC 70748-213

NDC codes

FDA NDC Directory

Product NDC (as listed)70748-213Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70748-0213Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70748-213-06	70748021306	1 BOTTLE in 1 CARTON (70748-213-06) / 30 TABLET in 1 BOTTLEMarketed from Jan 30, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dasatinib
Generic name (nonproprietary): dasatinib
Active ingredients: Dasatinib — 140 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Lupin Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214350
Marketing start: Jan 30, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 3A4 Inhibitors (Mechanism)Protein Kinase Inhibitors (Mechanism)
Identifiers: Product ID 70748-213_79f45560-3318-42e3-8be6-fac133dca745SPL ID 79f45560-3318-42e3-8be6-fac133dca745SPL set ID f60261dd-b8ea-4511-bed6-ad6d7f4dd828RxCUI 643105, 643107, 643109, 799047, 1045402, 1045406UNII RBZ1571X5H
Pharmacologic class: Kinase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470748021306 followed by a unit qualifier and the quantity

Package 70748-0213-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 27, 2026.

Indications (excerpt from the label)

Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. Newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are kinase inhibitor indicated for the treatment of newly diagnose…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 214350

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214350
Product	Strength	Form · route	Labeler	Product NDC
Dasatinib	Dasatinib 70 mg/1	TabletOral	Lupin Pharmaceuticals, Inc.	70748-210
Dasatinib	Dasatinib 20 mg/1	TabletOral	Lupin Pharmaceuticals, Inc.	70748-208
Dasatinib	Dasatinib 50 mg/1	TabletOral	Lupin Pharmaceuticals, Inc.	70748-209
Dasatinib	Dasatinib 80 mg/1	TabletOral	Lupin Pharmaceuticals, Inc.	70748-211
Dasatinib	Dasatinib 100 mg/1	TabletOral	Lupin Pharmaceuticals, Inc.	70748-212